US Drug Recall Register

FDA Drug Recalls

14,801 recalls, newest first

Class II · Moderate risk Terminated

Clindamycin 300 mg capsules

Reason Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Prescript Pharmaceuticals, Inc. D-0808-2018
Class II · Moderate risk Terminated

Chlorhexidine 0.12% liquid

Reason Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Prescript Pharmaceuticals, Inc. D-0807-2018
Class II · Moderate risk Terminated

Acetaminophen 300 mg with Codeine Phosphate 30 mg tablets

Reason Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Prescript Pharmaceuticals, Inc. D-0806-2018
Class II · Moderate risk Terminated

Clindamycin 150 mg capsules

Reason Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Prescript Pharmaceuticals, Inc. D-0805-2018
Class II · Moderate risk Terminated

Papaverine 30mg/Phentolamine 2mg/Prostaglandin 20mcg/mL

Reason Lack of assurance of sterility: Upon review of recent 3rd party environmental certification documentation, it was determined that airflow patterns may not be sufficient to support the aseptic production of certain injectable drug products.

Vitalab Pharmacy, Inc D-0733-2018
Class II · Moderate risk Terminated

Papaverine 30mg/Phentolamine 1.5mg/Prostaglandin 50mcg/mL

Reason Lack of assurance of sterility: Upon review of recent 3rd party environmental certification documentation, it was determined that airflow patterns may not be sufficient to support the aseptic production of certain injectable drug products.

Vitalab Pharmacy, Inc D-0732-2018
Class II · Moderate risk Terminated

Methionine 25mg/Inositol 50mg/Choline 50mg/Cyanocobalamin 1mg/ml

Reason Lack of assurance of sterility: Upon review of recent 3rd party environmental certification documentation, it was determined that airflow patterns may not be sufficient to support the aseptic production of certain injectable drug products.

Vitalab Pharmacy, Inc D-0731-2018
Class II · Moderate risk Terminated

Papaverine 9mg/Phentolamine 1mg/Atropine 0.1mg/Prostaglandinl 10mcg/ml

Reason Lack of assurance of sterility: Upon review of recent 3rd party environmental certification documentation, it was determined that airflow patterns may not be sufficient to support the aseptic production of certain injectable drug products.

Vitalab Pharmacy, Inc D-0730-2018
Class II · Moderate risk Terminated

Alprostadil 20 mcg/mL

Reason Lack of assurance of sterility: Upon review of recent 3rd party environmental certification documentation, it was determined that airflow patterns may not be sufficient to support the aseptic production of certain injectable drug products.

Vitalab Pharmacy, Inc D-0729-2018
Class II · Moderate risk Terminated

Methylcobalamin for injection

Reason Lack of assurance of sterility: Upon review of recent 3rd party environmental certification documentation, it was determined that airflow patterns may not be sufficient to support the aseptic production of certain injectable drug products.

Vitalab Pharmacy, Inc D-0728-2018
Class II · Moderate risk Terminated

Metoprolol Succinate Extended-Release Tablets

Reason Presence of Foreign Tablets/Capsules: One foreign tablet identified as Clopidogrel 75 mg was found in a 100 count bottle of Metoprolol Succiante Extended-Release Tablets.

Dr. Reddy's Laboratories, Inc. NDC 55111-468-01 D-0727-2018
Class III · Low risk Terminated

Diltiazem HCl Extended-Release Capsules

Reason Failed Dissolution Specifications. High dissolution results were obtained during stability testing.

Mckesson Packaging Services D-0716-2018
Class III · Low risk Terminated

Diltiazem CD

Reason Failed Dissolution Specifications. High dissolution results were obtained during stability testing.

Mckesson Packaging Services NDC 63739-284-10 D-0715-2018
Class III · Low risk Terminated

Diltiazem HCl Extended-Release Capsules

Reason Failed Dissolution Specifications. High dissolution results were obtained during stability testing.

Mckesson Packaging Services D-0714-2018
Class II · Moderate risk Terminated

Sulfamethoxazole and Trimethoprim Tablets USP

Reason Presence of Foreign Substance:Sun Pharma is recalling one (1) lot of Sulfamethoxazole and Trimethoprim Tablets USP, 800 mg/160 mg (500 ct.) because a foreign matter identified as polyethylene was detected in two (2) tablets.

Sun Pharmaceutical Industries, Inc. NDC 53489-146-05 D-0802-2018
Class III · Low risk Terminated

Aptensio XR

Reason Failed Dissolution Specification: Low dissolution outside of specifications

Rhodes Pharmaceuticals, L.P. NDC 42858-402-45 D-0710-2018
Class I · High risk Terminated

Euphoric Premium Male Performance Enhancer capsules

Reason Marketed Without An Approved NDA/ANDA: product contains undeclared sildenafil, tadalafil, and oxytetracycline, FDA approved drug products making Euphoric an unapproved drug.

Epic Products, LLC D-0288-2019
Class III · Low risk Terminated

OraVerse

Reason Failed Impurities/Degradation: This recall has been initiated due to an out of specification (OOS) result that was obtained for related substance (Phentolamide), a known degradation product impurity at the 15 month stability test point.

Septodont Inc. NDC 0362-0101-10 D-0828-2018
Class III · Low risk Terminated

Calendula Cream

Reason Labeling: Labeling Error on Declared Strength; The outer carton (secondary packaging) statement of ingredients misstates the concentration of active ingredient at 7%. The primary packaging (tube) correctly states the active ingredient at 10%.

Boiron Inc. D-0803-2018
Class I · High risk Terminated

Rhino 69 Extreme 50000 packaged in 1 capsule per blister pack

Reason Marketed Without An Approved NDA/ANDA: FDA analysis found the product to contain undeclared tadalafil. The presence of tadalafil makes Rhino Extreme 50000 an unapproved drug for which safety and efficacy have not been established and, therefore, subject to recall.

AMA Wholesale D-0821-2018
Class II · Moderate risk Terminated

NEOstigmine Methylsulfate

Reason Lack of Assurance of Sterility:Microbial contamination was detected during routine testing of subsequent unreleased product lots due to interaction between the product syringe and tamper evident container closure, which may result in the potential introduction of microorganisms into the products.

Premier Pharmacy Labs Inc NDC 69623-234-14 D-0702-2018